Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Anna James-Bott

Multidisciplinary scientist working on single cell approaches to overcome drug resistance in Multiple Myeloma.

Project Background

Multiple myeloma (MM) is a cancer of plasma cells, accounting for 2% of cancers, responsible for 3000 deaths every year in the UK alone. MM is incurable and has a poor prognosis, with a five-year survival rate of 47%. Multiple treatment strategies are employed for MM patients, including proteasome inhibitors, immunomodulatory drugs and corticosteroids. Although these drug treatments are effective at MM cell killing, patients eventually become refractory and resistant to further treatment. Anti-cancer drug resistance is one of the biggest limitations in treatment of MM. Therefore it is imperative to understand the mechanisms involved in the development of the resistant phenotype, and to find compounds that could reverse this phenotype and make patients treatment-sensitive again. 

MM is an incredibly heterogeneous disease both inter and intra-individual. This means that single-cell techniques are required to fully reflect the variation seen in the population and of the cells within the tumour microenvironment. 

ABOUT ME

I obtained my BSc in Natural Sciences (Biomedical Sciences and Mathematics & Statistics) from University College London, with First Class Honours. I completed a summer studentship in the Department of Physiology, Anatomy and Genetics at Oxford, funded by the British Heart Foundation,  and that motivated me to apply to the University of Oxford CDT programme SABS for a DPhil. 

Currently I am working in NDORMS as part of the Oppermann Group, researching proteasome inhibitor resistance in Multiple Myeloma. I am involved as both a wet-lab scientist and as a bioinformatician,  generating workflows for next generation sequencing data analysis. 

I am funded by the Engineering and Physical Sciences Research Council (EPSRC) and GlaxoSmithKline (GSK). 

----------------------------------------------------------

In my spare time I enjoy all things sports, including: rowing and coxing for St Hilda's College Boat Club, competing in sport karate, playing lacrosse and playing/watching football.